LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma USA - English APAC - English Japan - Japanese USA - English
Nyenta.com/10316134

Trending...
SEOUL, South Korea, June 19, 2025 ~ LOTTE BIOLOGICS Signs Contract Manufacturing Agreement with Ottimo Pharma for Antibody Therapeutics

On June 19, 2025, LOTTE BIOLOGICS, a leading contract development and manufacturing organization (CDMO), announced the signing of a contract manufacturing agreement with Ottimo Pharma. The agreement was signed at the LOTTE BIOLOGICS booth within the Boston Convention and Exhibition Center, where BIO INTERNATIONAL 2025 is currently being held.

Ottimo Pharma is a biopharmaceutical company that specializes in developing first-in-class, one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of people living with cancer. Through this partnership, LOTTE BIOLOGICS will produce antibody drug substance for Ottimo Pharma's Jankistomig at its Syracuse Bio Campus in New York.

James Park, CEO of LOTTE BIOLOGICS, expressed his excitement about the collaboration stating, "This agreement serves as further validation of our competitiveness as a CDMO in the global antibody therapeutics market. We will continue striving not only to supply high-quality medicines that meet global standards but also to become a company that delivers greater value to both our partners and patients."

More on Nyenta.com
Joseph Shultz, Vice President Technical Development & Manufacturing at Ottimo PHARMA also shared his thoughts on the partnership saying, "This manufacturing collaboration marks a significant milestone in our commitment to advancing Jankistomig with speed and precision. Partnering with Lotte's proven biomanufacturing capabilities enhances our operational readiness and supports our rapid path to IND submission and clinical trial initiation."

LOTTE BIOLOGICS is currently providing CDMO services at its Syracuse Bio Campus which includes cell line development and large-scale contract manufacturing of biopharmaceuticals. The company also has plans to begin operations at Plant 1 in its Songdo Bio Campus by 2027. This facility will have a production capacity of 120,000 liters and will enable the company to handle major global contracts.

In recent years, LOTTE BIOLOGICS has been expanding its partnerships with various global biopharmaceutical companies in Asia and Europe. With its two production hubs in North America and Asia, the company is solidifying its position in the CDMO market for not only antibody therapeutics but also ADC modalities. LOTTE BIOLOGICS aims to secure clients by providing an integrated service through collaboration and delivering superior and trustworthy solutions.

More on Nyenta.com
Moreover, LOTTE BIOLOGICS has entered into strategic collaborations with global contract development organizations (CDOs) and drug product (DP) companies to provide client-specific end-to-end services. Through these partnerships, the company offers fully customized CDMO solutions spanning early drug development to commercialization.

This contract manufacturing agreement between LOTTE BIOLOGICS and Ottimo Pharma is a significant step towards advancing the development of innovative antibody therapeutics for cancer patients. With their combined expertise and capabilities, this partnership is expected to bring about positive outcomes in the fight against cancer.
Filed Under: Business
Show All News | Disclaimer | Report Violation

0 Comments

Latest on Nyenta.com